000000763 001__ 763
000000763 005__ 20250424232545.0
000000763 0247_ $$2DOI$$a10.6083/M4154F2N
000000763 037__ $$aETD
000000763 245__ $$aTowards a structural understanding of adeno-associated virus serotype 2 and its recognition by antibodies
000000763 260__ $$bOregon Health and Science University
000000763 269__ $$a2012-05-01
000000763 336__ $$aDissertation
000000763 502__ $$bPh.D.
000000763 520__ $$aAdeno-­‐associated virus (AAV) is a leading candidate as a gene therapy vector, but as with other vectors, one of the limitations is a host-neutralizing immune response.
000000763 542__ $$fIn copyright - single owner
000000763 650__ $$aAntibodies, Monoclonal$$014854
000000763 650__ $$aEpitopes$$014882
000000763 650__ $$aDependovirus$$014224
000000763 650__ $$aTumor Necrosis Factor alpha-Induced Protein 3$$012043
000000763 650__ $$aGenetic Therapy$$028314
000000763 650__ $$aAntibodies, Monoclonal$$014854
000000763 650__ $$aAdenoviridae$$014249
000000763 6531_ $$aantigenic determinants
000000763 691__ $$aSchool of Medicine$$041369
000000763 692__ $$aDepartment of Biochemistry and Molecular Biology$$041396
000000763 7001_ $$aMcCraw, Dustin$$uOregon Health and Science University$$041354
000000763 7201_ $$aChapman, Michael$$uOregon Health and Science University$$041354$$7Personal$$eAdvisor
000000763 8564_ $$9dc4973dc-0c43-461e-a047-207b4dd58f9f$$s2863614$$uhttps://digitalcollections.ohsu.edu/record/763/files/766_etd.pdf$$ePublic$$2b36672941ae1c5b71bde2b8c37db7b84$$31
000000763 905__ $$a/rest/prod/2v/23/vt/42/2v23vt426
000000763 909CO $$ooai:digitalcollections.ohsu.edu:763$$pstudent-work
000000763 980__ $$aTheses and Dissertations